Cargando…
Estimated Clinical Trial Capacity of Sites Participating in the COVID-19 Convalescent Plasma Expanded Access Program
This cross-sectional study estimates the trial capacity of sites participating in the COVID-19 convalescent plasma expanded access program.
Autores principales: | Gustafson, M. Sage, Patel, Aman, Hong, Chuan, Meline, Miles, Peña, Daniella, Tang, Charis, Fernandez Lynch, Holly |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582895/ https://www.ncbi.nlm.nih.gov/pubmed/36260335 http://dx.doi.org/10.1001/jamanetworkopen.2022.37540 |
Ejemplares similares
-
Devil in the Details: Physician Duties and Expanded Access
por: Lynch, Holly Fernandez
Publicado: (2023) -
Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study
por: Senefeld, Jonathon W., et al.
Publicado: (2021) -
Navigating the Expanded Access Pathway to Investigational Drugs as an Academic Oncologist
por: Fernandez Lynch, Holly, et al.
Publicado: (2023) -
2091. Use of Telehealth to Expand Antimicrobial Stewardship Capacity Among Critical Access Hospitals in Washington State
por: Kvak, Staci, et al.
Publicado: (2019) -
Perspectives of Academic Oncologists About Offering Expanded Access to Investigational Drugs
por: Gould, Patrick, et al.
Publicado: (2022)